Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

Sponsor

International Extranodal Lymphoma Study Group (IELSG) (Other)

Overall Status

Completed

CT.gov ID

NCT01011920

Collaborator

(none)

126

Enrollment

Locations

Arms

Duration (Months)

5.5

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a multicenter open label randomized phase II trial.

Enrolled Primary Central Nervous System Lymphoma (PCNSL) patients will be stratified according to the IELSG score and randomized to receive one of the follows as primary chemotherapy:

Arm A: Methotrexate (MTX) + Cytarabine (Ara-C)
Arm B: MTX + Ara-C + rituximab
Arm C: MTX + Ara-C + rituximab + thiotepa.

Chemotherapy will be administered every three weeks. The maximum number of chemotherapy induction courses will be 4. Patients in Stable Disease (SD) or better after two courses will receive two more courses of the same primary chemotherapy regimen. Stem-cells harvest will be performed in the three arms after the second course. After 4 courses response assessment will be performed.

Patients who will not achieve SD or better after the 4th course, as well as those who will experience Progressive Disease (PD) at any time and those who will not achieve a sufficient stem cell harvest, will receive Whole Brain Radiation Therapy (WBRT) 36-40 Gy +/- tumor bed boost of 9 Gy.

Patients who will achieve SD or better after the 4th course will be stratified according to objective response to primary chemotherapy and to primary chemotherapy regimen and randomly allocated to receive as consolidation therapy one of the follows:

Arm D: WBRT 36 Gy +/- boost 9 Gy
Arm E: Carmustine (BCNU) + Thiotepa + Autologous Peripheral Blood Stem Cell Transplant (APBSCT) Patients in Complete Response (CR) after WBRT or APBSCT will remain in follow-up. Patients who will not achieve a CR after WBRT will be managed according to physician's preferences. Patients who will not achieve a CR after APBSCT will be referred to WBRT.

Condition or Disease	Intervention/Treatment	Phase
Central Nervous System Lymphoma	Drug: Methotrexate Drug: Ara-C Drug: Rituximab Drug: Thiotepa Radiation: radiotherapy Drug: BCNU Other: APBSCT	Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

126 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Transplantation For Immunocompetent Patients With Newly Diagnosed Primary CNS Lymphoma

Study Start Date :

Nov 1, 2009

Actual Primary Completion Date :

Mar 1, 2015

Actual Study Completion Date :

Mar 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: MTX+ AraC Arm A Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3	Drug: Methotrexate Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses. Drug: Ara-C Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses Other Names: Cytarabine
Experimental: Ara-C +Rituximab Arm B Rituximab 375 mg/m2 conventional infusion d -5 & 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3	Drug: Ara-C Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses Other Names: Cytarabine Drug: Rituximab Rituximab 375 mg/m2 conventional infusion on day - 5 & 0 every 3 weeks for a maximum of 4 cycles Other Names: MabThera
Experimental: Ara-C + rituximab+thiotepa Arm C Rituximab 375 mg/m2 conventional infusion d -5 & 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3 Thiotepa 30 mg/m2 30 min. Infusion d 4	Drug: Ara-C Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses Other Names: Cytarabine Drug: Rituximab Rituximab 375 mg/m2 conventional infusion on day - 5 & 0 every 3 weeks for a maximum of 4 cycles Other Names: MabThera Drug: Thiotepa ARM C: Thiotepa 30 mg/m2 (30 min. Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 & -4
Experimental: WBRT 36 Gy +/- boost 9 Gy ARM D: WBRT with 36 Gy in the case of CR to primary chemotherapy or the same WBRT dose followed by a tumor-bed boost of 9 Gy with 1-2 cm of margin surrounding enhanced residual lesion (total tumor-bed dose 45 Gy) in patients who achieved a PR or SD after primary chemotherapy. Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions.	Radiation: radiotherapy Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions. Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the orbits, which must be shielded after 30 Gy (after 36 Gy in the case of evident intraocular disease at diagnosis). Tumor-bed (boost or partial-brain RT) will be irradiated by 2 to 4 isocentric treatment fields based on tumor location, with all portals treated per each RT session.
Experimental: BCNU + Thiotepa + APBSCT Arm E BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6 Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 & -4 Reinfusion of PBSC ≥5 x 106 CD34+ cells/kg day 0	Drug: Thiotepa ARM C: Thiotepa 30 mg/m2 (30 min. Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 & -4 Drug: BCNU BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6 Other Names: Carmustine Other: APBSCT Autologous peripheral blood stem cell transplant (APBSCT)

Outcome Measures

Primary Outcome Measures

response rate after primary chemotherapy and 2 years failure free survival at second randomization [3 months, 2 years]

Secondary Outcome Measures

safety, as acute and long-term toxicity [Throughout all the active treatment period]
overall survival [From entry onto trial until death for any cause]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Histological or cytological assessed diagnosis of non-Hodgkin's lymphoma.
Diagnostic sample obtained by stereotactic or surgical biopsy, Cerebrospinal Fluid (CSF) cytology examination or vitrectomy.
Disease exclusively localized into the central nervous system, CSF, cranial nerves or eyes.
At least one measurable lesion.
Previously untreated patients (previous or ongoing steroid therapy admitted).
Age 18-65 years (with ECOG Performance Status 0-3) or 66-70 (with ECOG Performance Status 0-2).
Adequate bone marrow, renal, cardiac, and hepatic function.
Sexually active patients of childbearing potential agreeing in implementing adequate contraceptive measures during study participation.
Absence of any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
Patient-signed informed consent obtained before registration.

Exclusion Criteria:

Patients with lymphomatous lesions outside the CNS.
Patients with a previous non-Hodgkin lymphoma at any time.
Previous or concurrent malignancies with the exception of surgically cured carcinoma in-situ of the cervix, carcinoma of the skin or other cancers without evidence of disease at least from 5 years.
HBsAg and HCV positivity.
HIV infection, previous organ transplantation or other clinically evident form of immunodeficiency.
Concurrent treatment with other experimental drugs.
Concurrent Pregnancy or lactation.
Patients not agreeing to take adequate contraceptive measures during the study.
Symptomatic coronary artery disease, cardiac arrhythmias uncontrolled with medication or myocardial infarction within the last 6 months (New York Heart Association Class III or IV heart disease).

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	University Hospital	Aachen	Germany
2	Universitätsklinikum Erlangen	Erlangen	Germany
3	"Klinik für Hämatologie Universitätsklinikum Essen"	Essen	Germany
4	Uniklinik Freiburg	Freiburg	Germany
5	Universitätskrankenhaus Hamburg-Eppendorf	Hamburg	Germany
6	Friedrich Schiller Universitaet Jena	Jena	Germany
7	Johannes Gutenberg Universität Mainz	Mainz	Germany
8	Technische Universität in München	München	Germany
9	Universitätsklinikum Ulm	Ulm	Germany
10	A.O. SS. Antonio e Biagio e Cesare Arrigo	Alessandria	Italy
11	Spedali Civili	Brescia	Italy
12	San Raffaele H Scientific Institute	Milan	Italy
13	Ospedale Umberto I	Nocera Inferiore	Italy
14	Ospedale Civile S.Spirito	Pescara	Italy
15	Arcispedale Santa Maria Nuova	Reggio Emilia	Italy
16	Istituto Nazionale dei Tumori Regina Elena	Roma	Italy
17	Università degli Studi La Sapienza	Roma	Italy
18	Humanitas	Rozzano	Italy
19	Ospedale Maggiore S. Giovanni Battista	Torino	Italy
20	Policlinico G.B. Rossi	Verona	Italy
21	IOSI - Oncology Institute of Southern Switzerland	Bellinzona	Switzerland	6500
22	Nottingham City Hospital	Nottingham	United Kingdom
23	Queen's Hospital	Romford	United Kingdom

Sponsors and Collaborators

International Extranodal Lymphoma Study Group (IELSG)

Investigators

Study Chair: Andrés JM Ferreri, MD, San Raffaele H Scientific Institute, Milan, Italy
Study Chair: Gerald Illerhaus, MD, University Medical Center, Freiburg, Germany
Principal Investigator: Emanuele Zucca, MD, IOSI, Bellinzona, Switzerland